BlackRock, Inc. 13D and 13G filings for Arcutis Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
BLACKROCK INC BLK |
9,029,624 7.700% |
0 (Unchanged) |
Filing |
| 2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
BLACKROCK INC BLK |
9,029,624 7.700% |
3,113,078 (+52.62%) |
Filing |
| 2024-01-29 3:26 pm Purchase |
2023-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
BLACKROCK INC BLK |
5,916,546 6.300% |
2,036,144 (+52.47%) |
Filing |
| 2023-11-07 3:33 pm Sale |
2023-10-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
BLACKROCK INC BLK |
3,880,402 4.100% |
-1,333,856 (-25.58%) |
Filing |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
BLACKROCK INC BLK |
5,214,258 8.600% |
900,394 (+20.87%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
BLACKROCK INC BLK |
4,313,864 8.600% |
1,418,810 (+49.01%) |
Filing |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
BLACKROCK INC BLK |
2,895,054 6.600% |
2,895,054 (New Position) |
Filing |